0000899243-20-017516.txt : 20200623 0000899243-20-017516.hdr.sgml : 20200623 20200623200142 ACCESSION NUMBER: 0000899243-20-017516 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200619 FILED AS OF DATE: 20200623 DATE AS OF CHANGE: 20200623 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brown Bob D CENTRAL INDEX KEY: 0001598479 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36281 FILM NUMBER: 20983566 MAIL ADDRESS: STREET 1: 87 CAMBRIDGEPARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER NAME: FORMER CONFORMED NAME: Brown Bob DATE OF NAME CHANGE: 20140129 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc CENTRAL INDEX KEY: 0001399529 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205993609 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617 621 8097 MAIL ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-19 0 0001399529 Dicerna Pharmaceuticals Inc DRNA 0001598479 Brown Bob D C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 See Remarks Common Stock 2020-06-19 4 M 0 9670 2.97 A 14670 D Common Stock 2020-06-19 4 S 0 9670 25.00 D 5000 D Employee Stock Option (Right to Buy) 2.97 2020-06-19 4 M 0 9670 0.00 D 2027-01-03 Common Stock 9670 21876 D The Reporting Person sold an aggregate of 9,670 shares of common stock on June 19, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 0.98% of 990,997 shares of common stock, which is the number of shares of common stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2019. The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date. Chief Scientific Officer, EVP of R&D Exhibit 24 - Power of Attorney /s/ Douglas W. Pagan, attorney-in-fact 2020-06-23 EX-24 2 attachment1.htm EX-24 DOCUMENT

                         LIMITED POWER OF ATTORNEY FOR
                        SECTION 16 REPORTING OBLIGATIONS

       Know all by these presents, that the undersigned hereby makes,
constitutes and appoints each of Douglas Fambrough, Douglas W. Pagan and Tim
Bernstein, or either of them acting individually, and with full power of
substitution, the undersigned's true and lawful attorney-in-fact to:

     (1)    prepare, execute in the undersigned's name and on the undersigned's
            behalf, and submit to the U.S. Securities and Exchange Commission
            (the "SEC") a Form ID, including amendments thereto, and any other
            documents necessary or appropriate to obtain codes and passwords
            enabling the undersigned to make electronic filings with the SEC of
            reports required by Section 16(a) of the Securities Exchange Act of
            1934 (the "Exchange Act") or any rule or regulation of the SEC;

     (2)    execute for and on behalf of the undersigned, in the undersigned's
            capacity as an officer and/or director of Dicerna Pharmaceuticals,
            Inc., a Delaware corporation (the "Company"), Forms 3, 4, and 5,
            including amendments thereto, in accordance with Section 16(a) of
            the Exchange Act and the rules and regulations thereunder;

     (3)    seek or obtain, as the undersigned's representative and on the
            undersigned's behalf, information on transactions in the Company's
            securities from any third party, including brokers, employee benefit
            plan administrators and trustees, and the undersigned hereby
            authorizes any such person to release any such information to such
            attorney-in-fact and approves and ratifies any such release of
            information;

     (4)    do and perform any and all acts for and on behalf of the undersigned
            which may be necessary or desirable to complete and execute any such
            Form 3, 4, or 5, complete and execute any amendment or amendments
            thereto, and timely file such form with the SEC and any stock
            exchange or similar authority; and

     (5)    take any other action of any type whatsoever in connection with the
            foregoing which, in the opinion of such attorney-in-fact, may be of
            benefit to, in the best interest of, or legally required by, the
            undersigned, it being understood that the documents executed by such
            attorney-in-fact on behalf of the undersigned pursuant to this Power
            of Attorney shall be in such form and shall contain such terms and
            conditions as such attorney-in-fact may approve in such
            attorney-in-fact's discretion.

       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming nor relieving, nor is the Company assuming nor
relieving, any of the undersigned's responsibilities to comply with Section 16
of the Exchange Act.  The undersigned acknowledges that neither the Company nor
the foregoing attorneys-in-fact assume (i) any liability for the undersigned's
responsibility to comply with the requirement of the Exchange Act, (ii) any
liability of the undersigned for any failure to comply with such requirements,
or (iii) any obligation or liability of the undersigned for profit disgorgement
under Section 16(b) of the Exchange Act.

       This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee of
the Company.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 23rd day of June, 2020.



                                                /s/ Bob D. Brown
                                                ----------------------------
                                                Signature

                                                Bob D. Brown
                                                -----------------------------
                                                Print Name